The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment
Abstract
Liver cancer is the second leading cause of cancer‐related deaths, and hepatocellular carcinoma (HCC) is the most common type. Therefore, molecular targets are urgently required for the early detection of HCC and the development of novel therapeutic approaches. Glypican‐3 (GPC3), an oncofetal proteoglycan anchored to the cell membrane, is normally detected in the fetal liver but not in the healthy adult liver. However, in HCC patients, GPC3 is overexpressed at both the gene and protein levels, and its expression predicts a poor prognosis. Mechanistic studies have revealed that GPC3 functions in HCC progression by binding to molecules such as Wnt signaling proteins and growth factors. Moreover, GPC3 has been used as a target for molecular imaging and therapeutic intervention in HCC. To date, GPC3‐targeted magnetic resonance imaging, positron emission tomography, and near‐infrared imaging have been investigated for early HCC detection, and various immunotherapeutic protocols targeting GPC3 have been developed, including the use of humanized anti‐GPC3 cytotoxic antibodies, treatment with peptide/DNA vaccines, immunotoxin therapies, and genetic therapies. In this review, we summarize the current knowledge regarding the structure, function, and biology of GPC3 with a focus on its clinical potential as a diagnostic molecule and a therapeutic target in HCC immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Sawada, Y., Yoshikawa, T., Nobuoka, D., Shirakawa, H., Kuronuma, T., Motomura, Y., Mizuno, S., Ishii, H., Nakachi, K., Konishi, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3044 · Cited by 302
Kowalik, M. A., Saliba, C., Pibiri, M., Perra, A., Ledda-Columbano, G. M., Sarotto, I., Ghiso, E., Giordano, S., & Columbano, A. (2011) · Hepatology · doi:10.1002/hep.24289 · Cited by 86
Wong, K.-F., Liu, A. M., Hong, W., Xu, Z., & Luk, J. M. (2016) · Oncotarget · doi:10.18632/oncotarget.12760 · Cited by 63
Cited by
Advances in the Early Diagnosis of Hepatocellular Carcinoma
Wang, W., & Wei, C. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.01.014 · Cited by 492
Small-molecule fluorescence-based probes for interrogating major organ diseases
Han, H.-H., Tian, H., Zang, Y., Sedgwick, A. C., Li, J., Sessler, J. L., He, X.-P., & James, T. D. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01183e · Cited by 366
Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression
Brassart-Pasco, S., Brézillon, S., Brassart, B., Ramont, L., Oudart, J.-B., & Monboisse, J. C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00397 · Cited by 335
Metadata
- Authors
- Zhou, F., Shang, W., Yu, X., & Tian, J.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2017-06-16
- Volume
- 38
- Issue
- 2
- Pages
- 741-767
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2624710378
- Cited by
- 397
- References
- 4
- FWCI
- 10.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment. https://app.cochat.ai/papers/10.1002/med.21455
- The paper
- Zhou, F., Shang, W., Yu, X., & Tian, J. (2018). Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment. Medicinal Research Reviews. https://doi.org/10.1002/med.21455
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.